Home » Newsletters » BioWorld Science

BioWorld Science

April 13, 2016

View Archived Issues

Novel MC2 receptor antagonists have different effect on corticosterone response to ACTH in vivo

Tobira Therapeutics and Dong-A enter licensing agreements

ZD-100 effectively lowers blood pressure in first-in-human trial

Biota Pharmaceuticals changes name to Aviragen Therapeutics

Merck & Co. patents IRAK-4 inhibitors

Merck & Co. reports HIF prolyl hydroxylase inhibitors

Arena Pharmaceuticals presents phase Ib results for APD-371

FDA accepts Remoxy NDA for review

Catabasis Pharmaceuticals initiates part B of MoveDMD trial

Positive interim review in ongoing AML WT1 T cell clinical trial

Oncternal Therapeutics receives license to develop ROR1 antibodies

Phase Ia study evaluates Ebola virus vaccination with VRC-EBOADC076-00-VP followed by MVA-EBOZ

FDA advisory committee makes recommendation on rociletinib NDA

Cantabio starts preclinical program for Alzheimer's disease

FDA awards fast track designation to Acura's LTX-04

Vaginal Proellex reduces excessive menstrual bleeding in phase IIb study

FDA accepts for review BLA for house dust mite sublingual allergy immunotherapy

FDA grants approval for phase II trial on Resunab

Calmodulin 2 and 3 mutations linked to infant cardiac arrest

FDA grants orphan drug designation to TGV-Inhalonix's Mul-1867

Cellecta develops approach to improve its CRISPR/Cas9 genome-wide screening plaform

Aortic valve stenosis induced in rabbits to study bisphosphonate effects on calcification

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...